Avantax Advisory Services Inc. Sells 1,084 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Avantax Advisory Services Inc. reduced its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 36.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,851 shares of the company's stock after selling 1,084 shares during the quarter. Avantax Advisory Services Inc.'s holdings in IDEXX Laboratories were worth $765,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. FSA Wealth Management LLC purchased a new position in shares of IDEXX Laboratories in the 3rd quarter worth $25,000. Rialto Wealth Management LLC bought a new position in shares of IDEXX Laboratories in the 4th quarter valued at about $30,000. Retirement Wealth Solutions LLC purchased a new position in IDEXX Laboratories in the fourth quarter worth about $31,000. Kestra Investment Management LLC bought a new stake in IDEXX Laboratories during the fourth quarter worth approximately $38,000. Finally, Crews Bank & Trust purchased a new stake in IDEXX Laboratories during the fourth quarter valued at approximately $41,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the transaction, the executive vice president now directly owns 8,176 shares in the company, valued at $3,781,645.28. This represents a 54.98 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director M Anne Szostak sold 3,000 shares of the business's stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the sale, the director now owns 3,061 shares of the company's stock, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.11% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on IDXX shares. Piper Sandler boosted their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research report on Monday, February 10th. Leerink Partnrs upgraded shares of IDEXX Laboratories to a "strong-buy" rating in a research report on Monday, December 2nd. Bank of America raised their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a report on Tuesday, February 4th. Leerink Partners began coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They set an "outperform" rating and a $500.00 price target for the company. Finally, Morgan Stanley reduced their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 29th. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $533.75.

IDEXX Laboratories Trading Up 0.6 %

Shares of NASDAQ IDXX traded up $2.61 during trading hours on Monday, reaching $423.60. The stock had a trading volume of 616,827 shares, compared to its average volume of 552,334. IDEXX Laboratories, Inc. has a 52-week low of $398.50 and a 52-week high of $548.88. The firm has a market cap of $34.34 billion, a price-to-earnings ratio of 39.70, a P/E/G ratio of 3.41 and a beta of 1.39. The business's fifty day moving average price is $437.36 and its two-hundred day moving average price is $444.76. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.